• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Optimization of a micro-neutralisation assay and its application in antigenic characterisation of influenza viruses

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses. 2015 Jun 13. doi: 10.1111/irv.12333. [Epub ahead of print]
[h=1]Optimization of a micro-neutralisation assay and its application in antigenic characterisation of influenza viruses.[/h] Lin Y[SUP]1[/SUP], Gu Y[SUP]1[/SUP], Wharton SA[SUP]1[/SUP], Whittaker L[SUP]1[/SUP], Gregory V[SUP]1[/SUP], Li X[SUP]1[/SUP], Metin S[SUP]1[/SUP], Cattle N[SUP]1[/SUP], Daniels RS[SUP]1[/SUP], Hay AJ[SUP]1[/SUP], McCauley JW[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The identification of antigenic variants and the selection of influenza viruses for vaccine production are based largely on antigenic characterisation of the haemagglutinin (HA) of circulating viruses using the haemagglutination inhibition (HI) assay. However, additional to evolution related to escape from host immunity, variants emerging as a result of propagation in different cell substrates can complicate interpretation of HI results.
[h=4]OBJECTIVES:[/h] The objective was to develop further a micro-neutralisation (MN) assay to complement the HI assay in antigenic characterisation of influenza viruses to assess the emergence of new antigenic variants and reinforce the selection of vaccine viruses.
[h=4]METHODS:[/h] A 96-well-plate plaque reduction MN assay based on measurement of the Infected Cell Population (ICP) using a simple imaging technique.
[h=4]RESULTS:[/h] Improvements to the plaque reduction MN assay included selection of the most suitable cell line according to virus type or subtype, and optimisation of experimental design and data quantitation. Comparisons of the results of MN and HI assays showed the importance of complementary data in determining the true antigenic relationships among recent human influenza A(H1N1)pdm09, A(H3N2) and type B viruses.
[h=4]CONCLUSIONS:[/h] Our study demonstrates that the improved MN assay has certain advantages over the HI assay: it is not significantly influenced by the cell-selected amino acid substitutions in the neuraminidase (NA) of A(H3N2) viruses, and it is particularly useful for antigenic characterisation of viruses which either grow to low HA titre and/or undergo an abortive infection resulting in an inability to form plaques in cultured cells. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.


[h=4]KEYWORDS:[/h] Influenza; antigenicity; haemagglutination inhibition; micro-neutralisation

PMID: 26073976 [PubMed - as supplied by publisher]
 
Back
Top Bottom